Clinical Trial Update: Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) [Phase 2]

View source ↗

Summary

A completed Phase II trial of single-agent irinotecan (Camptosar) in leukemia and lymphoma, with correlative laboratory studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Camptosar (irinotecan)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED